We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

U.S. Supreme Court Won’t Review 3rd Circuit’s Eyedrop Class Reversal

(May 22, 2018, 11:13 AM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on May 21 denied review of a prescription eyedrop case, sending the purported class action back to a New Jersey federal court for further proceedings (Alcon Laboratories, Inc., et al. v. Leonard Cottrell, et al., No. 17-1337, U.S. Sup.).

In 2014, Leonard Cottrell filed a purported class action against Alcon Laboratories Inc. and related entities; Allergan Inc. and related entities; Aton Pharra Inc., Bausch & Lomb Inc., Falcon Pharmaceuticals Ltd., Merck & Co. Inc., Pfizer Inc., Prasco LLC, Sandoz...
To view the full article, register now.